Key people
In the news
- Next week, Obulytix is on the move. 🌍 From Amsterdam to Lisbon and Boston, members of our team will be connecting with the international biotech and #AMR community, while our colleagues in #Ghent continue to move our science forward in the lab. Amsterdam 🇳🇱 Kristof Van Emelen and Henrik Luessen are excited to be presenting our science at the 2nd BioCentury Inc. Grand Rounds Steering Committee, which connects translational science with the right partners to advance drug development. Lisbon 🇵🇹 Guy Hermans will attend @GAMRIC
- Next-generation antibiotics development data release upcoming! 🚀 #GAMRIC2026 has designated Obulytix's poster as one of the top-rated abstracts in the 𝑁𝑒𝑤 𝑎𝑛𝑡𝑖𝑏𝑎𝑐𝑡𝑒𝑟𝑖𝑎𝑙 𝑜𝑟 𝑎𝑛𝑡𝑖𝑓𝑢𝑛𝑔𝑎𝑙 𝑐𝑙𝑎𝑠𝑠𝑒𝑠 category. If you attend #GAMRIC2026 in Lisbon on 𝟐𝟐-𝟐𝟒 𝐒𝐞𝐩𝐭𝐞𝐦𝐛𝐞𝐫 𝟐𝟎𝟐𝟔, come see our CSO Guy Hermans at our poster "𝑆𝑦𝑠𝑡𝑒𝑚𝑎𝑡𝑖𝑐 𝑒𝑛𝑔𝑖𝑛𝑒𝑒𝑟𝑖𝑛𝑔 𝑜𝑓 𝑙𝑦𝑠𝑖𝑛𝑠 𝑦𝑖𝑒𝑙𝑑𝑠 𝑠𝑒𝑟𝑢𝑚-𝑟𝑒𝑠𝑖𝑠𝑡𝑎𝑛𝑡 𝑎𝑛𝑑 𝑖𝑛 𝑣𝑖𝑣𝑜 𝑎𝑐𝑡𝑖𝑣𝑒 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑𝑠 𝑡𝑜𝑤𝑎𝑟𝑑𝑠
- The first half of 2026 has been an exciting and productive period for Obulytix. Over the past months, we had the opportunity to connect with scientists, clinicians, biotech innovators, investors and industry leaders across several key international events focused on infectious diseases and antimicrobial resistance and beyond. 📍AMR Conference 2026 - Basel (March 3-4) We joined one of the leading global conferences dedicated to antimicrobial resistance, where our team presented Obulytix's progress in developing Precision Lysin
- Behind Obulytix stands a leadership team where diverse expertise meets a shared ambition. With experience spanning drug discovery and development, biotechnology, synthetic biology, venture capital, and company building, the team brings a highly complementary skill set to the table. Together, Kristof Van Emelen, Maria Fonseca, Dennis Grimon, Guy Hermans, Sara Lambrechts, and Henrik Luessen are aligned around one goal: advancing precision lysin therapeutics to tackle antimicrobial resistance. By combining scientific depth with
- Why Europe must continue investing in biotech innovation Europe continues to produce world-class scientific discoveries. The real challenge is ensuring these innovations are also developed, financed, and translated into therapies that reach patients. A recent feature by Labiotech.eu highlights how VIB has spent the past 30 years building one of Europe's leading biotechnology ecosystems, while underscoring the importance of continued investment in biotech innovation to secure Europe's future. The article also recognizes Obulytix as
- Antibiotic resistance is one of the greatest challenges facing modern healthcare. As bacteria become increasingly resistant to existing treatments, vulnerable patients such as cancer patients, transplant recipients and ICU patients face a growing risk of life-threatening infections. At Obulytix, we are developing Precision Lysin Therapeutics (PLTs): a novel class of engineered biologics designed to selectively target and eliminate harmful bacteria. In this carousel, we explain what PLTs are, how they work and why they have the
- Exciting recognition for @Obulytix! Voka Oost-Vlaanderen recently featured our mission to develop the next generation of anti-infective therapies. As a spin-off from Universiteit Gent and KU Leuven, we are building Precision Lysin Therapeutics (PLTs), a novel class of targeted biologics designed to selectively eliminate harmful bacteria without driving #antimicrobial #resistance. By combining #synthetic #biology, #AI, and #machine #learning, we are accelerating the design of #lysins against #multidrug-resistant pathogens. Our
- Exciting recognition for Obulytix! Voka Oost-Vlaanderen recently featured our mission to develop the next generation of anti-infective therapies. As a spin-off from Universiteit Gent and KU Leuven, we are building Precision Lysin Therapeutics (PLTs), a novel class of targeted biologics designed to selectively eliminate harmful bacteria without driving #antimicrobial #resistance. By combining #synthetic #biology, #AI, and #machine #learning, we are accelerating the design of #lysins against #multidrug-resistant pathogens. Our
Something wrong or missing? Send an update. Fixed within 24 hours.